Cancer Rehabilitation May Be Appropriate for Every Type of Cancer

Commentary
Video

Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.

Cancer prehabilitation is an understudied area of interest for Jessica Cheng, MD, where she hopes to make strides with upcoming trials.

Specifically, her research will focus on studying patients with breast and gynecologic cancers who are receiving chemotherapy but have not yet undergone surgery. She hopes that working with patients at this time point will allow them to become as fit as possible, which may improve outcomes after surgery and further treatment.

Cheng, assistant clinical professor in the Department of Supportive Care Medicine at City of Hope, noted she is currently designing a trial for these populations and hopes that this research may allow patients to have more control over their diseases.

Transcript:

Cancer rehabilitation applies to all patients with any type of cancer [or] anyone with a body. Overall, because this field is on the more recent side with not too many specialists, there’s a lot of room for research in every disease type and every stage of disease. Personally, my interest is in cancer prehabilitation. The research has exploded exponentially and become an international phenomenon over the last 10 years.

This is something very recent, and I’m working on designing a trial for patients with breast cancer and gynecologic [cancers] who are undergoing chemotherapy before surgery so that we can catch them at the earliest time point. [This may allow us to] make them as fit as possible in their mind and body at the earliest point to give them the best chance with their cancer treatment. There has been a recent study that showed that in patients who are undergoing neoadjuvant chemotherapy for breast cancer, the [patients] who did an exercise and nutrition training program were able to achieve a good outcome with pathologic complete response in 53% of the cases vs 28% of people who did not do the program. [I had] a lot of times talking with patients about [how] chemotherapy is not an excuse to not do exercise. It should be your push to exercise with all that you have in you to help the chemotherapy potentially work better. It’s a way that they can have a measure of control over their cancer journey.

Reference

Sanft T, Harrigan M, McGowan C, et al. Randomized trial of exercise and nutrition on chemotherapy completion and pathologic complete response in women with breast cancer: the lifestyle, exercise, and nutrition early after diagnosis study. J Clin Oncol. 2023;41(34):5285-5295. doi:10.1200/JCO.23.00871

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content